Jun 2026 (Q2 FY26) — Aug 3, 2026
SI-BONE, Inc. Q2 FY26 — Strong Revenue Growth and Profitability Improvement Driven by Broad-Based Demand and New Product Pipeline
Read the full callSI-BONE (SIBN) earnings
- Jun 2026
- Jun 2026 (Q2 FY26)
- Dec 2025
SI-BONE earnings: last reported Mon, 3 Aug 2026, for the quarter ended Jun 2026.
Reported
The figures, each with its period
Each figure keeps its basis and period; nothing is filled in.
| Metric | Value | Change | Basis | Period | Note |
|---|---|---|---|---|---|
| Revenue | 56.0 | +15.2% YoY | Quarterly, as filed | Quarter to Jun 2026 | Revenue from operations as filed. |
| Operating margin | -8.6 | +5.8 pts YoY | Operating profit / revenue | Quarter to Jun 2026 | For the quarter; a change is in percentage points. |
| Net profit | -4.1 | Quarterly, as filed | Quarter to Jun 2026 | Profit after tax as filed. The year-earlier figure was zero or a loss, so no percentage is shown. |
Price
$19.91 +2.26% · +$0.44
Performance +30.5% 1Y
1Y: $15.26 on 14 Oct 2025 → $19.91. High $21.4 (7 Jan 2026), low $11.61 (11 May 2026).
- Previous close
- $19.47
- 52-week range
- $11.61 – $21.4
- One year
- +30.81%
Overview
- Symbol
- SIBN
- Sector
- Health Care
- Exchange
- US
- Currency
- USD
Call summaries
Every analysed call
SI-BONE earnings calls (SIBN)
Financials
What the filings say
Net profit, year on year: +34% (quarter to jun 2026 against jun 2025).
| Line item | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 40 | 49 | 47 | 49 | 49 | 56 | 53 | 56 |
| Operating profit | -8 | -5 | -7 | -7 | -5 | -2 | -5 | -5 |
| Operating margin | −18.9% | −11.2% | −15.8% | −14.4% | −11.1% | −4.4% | −9.7% | −8.6% |
| Interest | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Net profit | -7 | -4 | -7 | -6 | -5 | -2 | -4 | -4 |
| EPS ($ per share) | -0.16 | — | -0.15 | -0.14 | -0.11 | — | -0.10 | -0.09 |
| Line item | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Equity capital | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Reserves | -157 | -196 | -239 | -296 | -357 | -400 | -431 | -450 |
| Total liabilities | 48 | 54 | 54 | 56 | 59 | 61 | 63 | 61 |
| Fixed assets | 2 | 4 | 5 | 9 | 16 | 16 | 20 | 21 |
| Total assets | 139 | 117 | 223 | 191 | 158 | 230 | 230 | 239 |
| Line item | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Cash from operations | -15 | -32 | -31 | -40 | -42 | -19 | -12 | -1 |
| Cash from investing | -98 | 13 | -63 | 52 | -3 | -60 | 13 | 4 |
| Cash from financing | 115 | 3 | 136 | -2 | 2 | 91 | 2 | 3 |
| Net cash flow | 3 | -15 | 43 | 10 | -43 | 13 | 2 | 7 |
| Capital expenditure | -1 | -2 | -3 | -6 | -10 | -8 | -10 | -8 |
| Free cash flow | -15 | -34 | -33 | -46 | -51 | -27 | -23 | -9 |
Insider filings
130 filings between Nov 3, 2025 and Oct 12, 2026.
Open market
decisions to buy or sellPurchases
None
No insider bought shares.
Sales
$11.81M
106 sales by 7 insiders
30% filed under a 10b5-1 plan — scheduled in advance, not decided on the day
Compensation
not trading decisions- 15
- Award — granted as compensation
- 9
- Option exercise — converted options into shares
Who traded
open market only| Insider | Bought | Sold | Last filing |
|---|---|---|---|
| FRANCIS LAURA | — | $4.69M | Oct 12, 2026 |
| DUNN JEFFREY W | — | $3.51M | Oct 1, 2026 |
| Maheshwari Anshul | — | $1.86M | Oct 5, 2026 |
| PISETSKY MICHAEL A. | — | $1.12M | Oct 2, 2026 |
| RECUPERO ANTHONY J | — | $463.2K | Feb 17, 2026 |
| Davis Timothy E JR | — | $104.2K | May 29, 2026 |
| Nishimura Mika | — | $56.7K | Mar 12, 2026 |
Latest filings (50)
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| Oct 12, 2026 | FRANCIS LAURA Chief Executive Officer | Sale 10b5-1 plan | 38,006 | $762.0K |
| Oct 5, 2026 | Maheshwari Anshul Chief Op & Financial Officer | Sale 10b5-1 plan | 1,731 | $33.8K |
| Oct 2, 2026 | Maheshwari Anshul Chief Op & Financial Officer | Sale 10b5-1 plan | 1,560 | $28.3K |
| Oct 2, 2026 | Maheshwari Anshul Chief Op & Financial Officer | Sale 10b5-1 plan | 1,758 | $32.0K |
| Oct 2, 2026 | PISETSKY MICHAEL A. SVP, Ops & Adm/Chief Legal Ofr | Sale | 1,300 | $23.7K |
| Oct 2, 2026 | PISETSKY MICHAEL A. SVP, Ops & Adm/Chief Legal Ofr | Sale | 34 | $617 |
| Oct 2, 2026 | PISETSKY MICHAEL A. SVP, Ops & Adm/Chief Legal Ofr | Sale | 1,799 | $32.6K |
| Oct 1, 2026 | DUNN JEFFREY W Director | Option exercise | 20,000 | $93.6K |
| Oct 1, 2026 | DUNN JEFFREY W Director | Sale | 20,000 | $369.4K |
| Sep 1, 2026 | DUNN JEFFREY W Director | Sale 10b5-1 plan | 18,633 | $352.3K |
| Sep 1, 2026 | DUNN JEFFREY W Director | Sale 10b5-1 plan | 1,367 | $25.8K |
| Sep 1, 2026 | DUNN JEFFREY W Director | Option exercise 10b5-1 plan | 1,367 | $6.4K |
| Sep 1, 2026 | DUNN JEFFREY W Director | Option exercise 10b5-1 plan | 18,633 | $87.2K |
| Aug 24, 2026 | Maheshwari Anshul Chief Op & Financial Officer | Sale 10b5-1 plan | 11,636 | $234.0K |
| Aug 24, 2026 | FRANCIS LAURA Chief Executive Officer | Sale 10b5-1 plan | 25,972 | $522.6K |
| Aug 21, 2026 | FRANCIS LAURA Chief Executive Officer | Sale 10b5-1 plan | 3,923 | $78.5K |
| Aug 21, 2026 | Maheshwari Anshul Chief Op & Financial Officer | Sale 10b5-1 plan | 11,228 | $224.8K |
| Aug 20, 2026 | FRANCIS LAURA Chief Executive Officer | Sale 10b5-1 plan | 51,884 | $1.01M |
| Aug 19, 2026 | Maheshwari Anshul Chief Op & Financial Officer | Sale 10b5-1 plan | 5,747 | $112.4K |
| Aug 17, 2026 | Maheshwari Anshul Chief Financial Officer | Sale | 2,189 | $40.8K |
| Aug 17, 2026 | Maheshwari Anshul Chief Financial Officer | Sale | 2,476 | $46.3K |
| Aug 17, 2026 | PISETSKY MICHAEL A. SVP, Ops & Adm/Chief Legal Ofr | Sale | 1,871 | $34.9K |
| Aug 17, 2026 | PISETSKY MICHAEL A. SVP, Ops & Adm/Chief Legal Ofr | Sale | 1,854 | $34.5K |
| Aug 17, 2026 | FRANCIS LAURA Chief Executive Officer | Sale | 1,973 | $36.8K |
| Aug 17, 2026 | FRANCIS LAURA Chief Executive Officer | Sale | 2,236 | $41.8K |
| Aug 17, 2026 | FRANCIS LAURA Chief Executive Officer | Sale | 3,892 | $72.6K |
| Aug 17, 2026 | FRANCIS LAURA Chief Executive Officer | Sale | 3,203 | $59.8K |
| Aug 17, 2026 | FRANCIS LAURA Chief Executive Officer | Sale | 3,652 | $68.1K |
| Aug 3, 2026 | DUNN JEFFREY W Director | Sale | 20,000 | $369.2K |
| Aug 3, 2026 | DUNN JEFFREY W Director | Option exercise | 20,000 | $93.6K |
| Jul 2, 2026 | Maheshwari Anshul Chief Financial Officer | Sale | 1,560 | $26.1K |
| Jul 2, 2026 | PISETSKY MICHAEL A. SVP, Ops & Adm/Chief Legal Ofr | Sale | 1,301 | $21.8K |
| Jul 2, 2026 | Maheshwari Anshul Chief Financial Officer | Sale | 1,757 | $29.5K |
| Jul 2, 2026 | PISETSKY MICHAEL A. SVP, Ops & Adm/Chief Legal Ofr | Sale | 34 | $573 |
| Jul 2, 2026 | PISETSKY MICHAEL A. SVP, Ops & Adm/Chief Legal Ofr | Sale | 1,799 | $30.0K |
| Jun 5, 2026 | DUNN JEFFREY W Director | Sale | 3,575 | $54.5K |
| Jun 4, 2026 | HILLEMAN JERYL L Director | Award | 10,957 | $0 |
| Jun 4, 2026 | West Thomas A. Director | Award | 10,957 | $0 |
| Jun 4, 2026 | Freund John Gordon Director | Award | 10,957 | $0 |
| Jun 4, 2026 | Nishimura Mika Director | Award | 10,957 | $0 |
| Jun 4, 2026 | DUNN JEFFREY W Director | Award | 10,957 | $0 |
| Jun 4, 2026 | Davis Timothy E JR Director | Award | 10,957 | $0 |
| May 29, 2026 | Davis Timothy E JR Director | Sale | 3,500 | $49.5K |
| May 28, 2026 | Davis Timothy E JR Director | Sale | 3,780 | $54.7K |
| May 28, 2026 | Davis Timothy E JR Director | Option exercise | 12,064 | $52.1K |
| May 18, 2026 | FRANCIS LAURA Chief Executive Officer | Sale | 3,893 | $57.4K |
| May 18, 2026 | Maheshwari Anshul Chief Financial Officer | Sale | 2,189 | $32.1K |
| May 18, 2026 | Maheshwari Anshul Chief Financial Officer | Sale | 2,477 | $36.4K |
| May 18, 2026 | FRANCIS LAURA Chief Executive Officer | Sale | 2,236 | $32.8K |
| May 18, 2026 | PISETSKY MICHAEL A. SVP, Ops & Adm/Chief Legal Ofr | Sale | 1,854 | $27.1K |
Source: SEC Form 4 filings. Form 4 reports transactions, not the cap table — absence of filings says nothing about how much an insider owns, and a quiet window is not a signal.
Your own record
Start an Inve Case for SI-BONE, Inc.
Free account. Everything above stays public.
Write why you follow SI-BONE, Inc. and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.
Keep reading